Home › Therapeutic areas › Oncology › Melanoma
Melanoma (16 companies)
Companies with an active program in Melanoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $34.5M | 8 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $477M | 7 |
| EIKN | Eikon Therapeutics | Oncology | 1 | Phase 2 | $320M | 13 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $17.0B | 23 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $3.02B | 14 |
| IMTX | Immatics | Oncology | 3 | Phase 3 | $968M | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $238M | 5 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 6 | Approved | $1.60B | 15 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | $29.5M | 10 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.67B | 13 |
| CATX | Perspective Therapeutics | Oncology | 1 | Phase 1 | $95.9M | 4 |
| PHIO | Phio Pharmaceuticals | Oncology | 1 | Phase 1 | $9.6M | 4 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $4.11B | 4 |
| REPL | Replimune Group | Oncology | 2 | Approved | $2.05B | 5 |
| HURA | TuHURA Biosciences | Oncology | 1 | Phase 3 | $104M | 4 |
No companies match.